INSIGHTS ON DRUG DEVELOPMENT

  • Telltale Signs You’re With The Wrong CDMO

    Is your CDMO an asset or a hindrance? This article explores 10 red flags that signal your parter isn't carrying its weight on your journey to commercialization.

  • How Outsourcing Buffer Prep Enables A SARS-CoV-2 Vaccine

    As numerous therapeutic drug and vaccine candidates make their way through human clinical trials, companies are already planning for how to manufacture any successful molecule on a global scale.

  • End-To-End Thinking During Drug Product Development

    In this article, Dr. Kashif Ghaffar, process validation pharmacist at Pfizer’s Freiburg facility, discusses what needs to be considered during product development in preparation for commercial manufacture.

  • Pluripotent Stem Cell Expansion And Scale-Up

    Upstream process development is complex for stem cell therapies, because these therapies involve many manipulations during cell differentiation or even cell engineering. Decisions made early in research will impact the entire product life cycle, so it is important to consider a good process design early on.

DRUG DEVELOPMENT SOLUTIONS

  • The new Thermo Scientific™ HyPeak™ Chromatography System marks our entry into single-use downstream purification and is designed to meet the needs of process scale-up and cGMP manufacturing. The HyPeak Chromatography System utilizes modular, single-use fluid transfer assemblies, industry standard sensor technology, innovative valve technology, and robust automation to meet the needs of end users today while providing the flexibility to scale up processes in the future.

  • BIOVIA offers a comprehensive collection of solutions to support the development, maintenance and deployment of data science solutions. Lower the barrier to Artificial Intelligence with our prebuilt Machine Learning architectures or easily integrate your own from 3rd party tools such as Python and R. Expand the use and reuse of data, democratize advanced techniques and foster a knowledge-driven culture.

    BIOVIA Pipeline Pilot enables scientists to rapidly create, test and publish data science solutions that automate accessing, processing, modeling and reporting scientific data in a graphically-based, code-free environment. Additional libraries of out-of-the-box capabilities can also operationalize advanced scientific analyses and machine learning as enterprise tools.

  • The commercialization of a combination product can be a complex process that involves obtaining the proper data, choosing a drug delivery system, developing a regulatory strategy and conducting clinical trials—all of which can increase development risks and affect your molecule’s time to market.

  • The respiratory system provides an attractive drug-absorption target to treat local and systemic diseases and is increasingly used to deliver small molecules and biotherapeutics. As described in this technical brief, Lonza has extensive experience in formulation development and manufacturing of respiratory drug-delivery products from proof of concept (POC) to manufacturing of dry-powder inhaled (DPI) formulations. Our technical brief provides additional information.

  • BIOVIA modeling and simulation software allows scientists to create better performing, safer and more cost-effective products by connecting the virtual and real worlds to test concepts with minimum risk and lower costs.

    BIOVIA Materials Studio materials modeling and simulation application helps researchers predict and connect a material’s atomic and molecular structure with its properties and behavior.